Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

赛诺菲免疫学全球研发负责人Alyssa Johnsen博士对此表示：“这一认定是对riliprubart解决关键医疗空白潜力的重要认可。 我们将全力加速其临床开发进程，目标是尽早为饱受AMR折磨的移植患者带来变革性的治疗方案。” ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

In June 2025, Sanofi announced that its investigational drug riliprubart received orphan drug designation from the US FDA for treating antibody-mediated rejection in solid organ transplantation, ...

法国制药巨头赛诺菲公司宣布，美国FDA已授予其实验性药物riliprubart孤儿药资格认定，用于治疗实体器官移植中的抗体诱导排斥反应（RIA）。这一认定体现了赛诺菲致力于解决移植医学领域关键未满足需求的承诺，目前该领域仍面临重大挑战且尚无FDA批准 ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart is also currently being investigated in patients with chronic inflammatory demyelinating polyneuropathy, specifically in those refractory to standard of care (MOBILIZE; ClinicalTrials ...